Callahan Advisors LLC Acquires 1,312 Shares of Eli Lilly and Company $LLY

Callahan Advisors LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 7.9% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,972 shares of the company's stock after acquiring an additional 1,312 shares during the quarter. Eli Lilly and Company makes up 1.3% of Callahan Advisors LLC's portfolio, making the stock its 28th biggest position. Callahan Advisors LLC's holdings in Eli Lilly and Company were worth $14,010,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. WestEnd Advisors LLC raised its holdings in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC bought a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $27,000. Citizens National Bank Trust Department grew its stake in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after purchasing an additional 27 shares during the period. Financial Gravity Asset Management Inc. purchased a new stake in Eli Lilly and Company in the first quarter worth $40,000. Finally, TD Capital Management LLC grew its stake in Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company's stock worth $46,000 after purchasing an additional 31 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 1.7%

NYSE LLY opened at $826.20 on Thursday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $935.63. The stock has a market cap of $781.97 billion, a P/E ratio of 54.00, a P/E/G ratio of 1.16 and a beta of 0.47. The stock's fifty day moving average price is $745.96 and its 200-day moving average price is $766.28. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. During the same period in the prior year, the firm posted $3.92 earnings per share. The company's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Activity at Eli Lilly and Company

In related news, CEO David A. Ricks purchased 1,632 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director directly owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 4,514 shares of company stock valued at $2,894,841 over the last three months. 0.13% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages recently weighed in on LLY. DZ Bank raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 14th. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Wall Street Zen cut Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 20th. JPMorgan Chase & Co. reduced their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research note on Tuesday, September 16th. Finally, Guggenheim upped their price target on Eli Lilly and Company from $875.00 to $948.00 and gave the stock a "buy" rating in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $948.06.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.